INFORMATION NOTE: CYSTIC FIBROSIS DRUGS: INTERFACE ISSUES

Could you please disseminate to the appropriate individuals within your organisation

Dear Colleague

Use of tobramycin and dornase alfa for adults with cystic fibrosis.

I refer you to the attached AWMSG Enclosures No. 6/AWMSG/0307 and 3/AWMSG/1206 in relation to the prescribing of nebulised tobramycin and dornase alfa for adults with cystic fibrosis. An ‘opt-in approach’ was suggested by the All Wales Prescribing Advisory Group which would provide a stable, non-binding approach to support professionals wishing to prescribe these drugs under shared care arrangements, recognising that this would be subject to local agreement. This principle and attached templates have been endorsed by the All Wales Medicines Strategy Group at their meeting in March 2007. This decision was reached following extensive multi-professional consultation across the primary, secondary and tertiary sectors.

This information note has been prepared by the AWMSG Secretariat to support the draft minutes of the AWMSG Meeting held in March 2007.

Yours sincerely

Philip A. Routledge
Acting AWMSG Chairman